Juvederm XC announced - more comfortable injections

Allergan, Inc. announced today it has received approval from the U.S. Food and Drug Administration (FDA) for JUVÉDERM® XC, which is JUVÉDERM with a little xylocaine added in. Xylocaine, known in the U.S. as lidocaine, is a local anesthestic agent used for numbing the skin, and this should make the injection process significantly more comfortable for our patients.

JUVÉDERM® also received their "one year indication" from the FDA, which means they are now permitted to advertise as having "the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment".

In the clinical study comparing JUVÉDERM XC (with lidocaine) to regular non-lidocaine JUVÉDERM, 93 percent of patients reported less pain when treated with the new formulation of JUVÉDERM, while maintaining a similar safety and effectiveness profile to the non-lidocaine formulation of JUVÉDERM®.

Of course, don't use this product if you have a lidocaine allergy.